Macular pigment changes after cataract surgery with yellow-tinted intraocular lens implantation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 17 12 2020
accepted: 26 02 2021
entrez: 25 3 2021
pubmed: 26 3 2021
medline: 12 10 2021
Statut: epublish

Résumé

We previously reported that macular pigment optical density (MPOD) levels decreased during a long follow-up period after clear intraocular lens (IOL) implant surgery presumably due to excessive light exposure. We examined changes in MPOD levels in the eyes that received yellow-tinted IOL implant surgery. This was a prospective, observational study. Fifty-five eyes of 35 patients were studied. MPOD levels were measured with a dual-wavelength autofluorescence technique on day 4; months 1, 3, and 6; and years 1 and 2 postoperatively. The average optical densities at 0°- 2° eccentricities (local MPODs) and total volumes of MPOD (MPOVs) in the area within 1.5° and 9° eccentricities were analyzed. The mean local MPOD at baseline (on day 4) was 0.79 at 0°, 0.71 at 0.5°, 0.68 at 0.9°, and 0.32 at 2°. The mean MPOV within 1.5° and 9° at baseline was 2950 and 18,897, respectively. Local MPOD at 0.9° and 2° and MPOVs were slightly decreased at month 1 and increased after that. The increase reached statistical significance in local MPOD at 0.5° and 2° and MPOVs (Tukey-Kramer test). The changes in MPOV within 9° at year 2 [(MPOV on year 2 - MPOV on day 4) / MPOV on day 4] were from -0.21 to 1.18 (mean and standard deviation: 1.14 ± 0.28). The MPOV of 15 eyes increased more than 10% from the initial value, was maintained within 10% in 21 eyes, and deteriorated more than 10% in only 3 eyes. Local MPOD and MPOV tended to slightly decrease month 1 postoperatively and gradually increased after that, but the rates of increases in MPOD levels were small. Yellow-tinted IOLs that have a lower transmittance of blue light might be preferable for preserving MPOD levels after surgery.

Identifiants

pubmed: 33764992
doi: 10.1371/journal.pone.0248506
pii: PONE-D-20-39598
pmc: PMC7993776
doi:

Substances chimiques

Macular Pigment 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0248506

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eye (Lond). 2019 Aug;33(8):1203-1214
pubmed: 30894692
Int J Mol Sci. 2019 Apr 11;20(7):
pubmed: 30979028
Arch Ophthalmol. 2002 Nov;120(11):1551-8
pubmed: 12427071
Transl Vis Sci Technol. 2019 Dec 18;8(6):41
pubmed: 31867142
Annu Rev Nutr. 2003;23:171-201
pubmed: 12626691
Retin Cases Brief Rep. 2019 Jan 10;:
pubmed: 30640318
Indian J Ophthalmol. 2012 Nov-Dec;60(6):561-3
pubmed: 23202400
Invest Ophthalmol Vis Sci. 1993 May;34(6):2033-40
pubmed: 8491553
Retina. 2016 Apr;36(4):787-90
pubmed: 26441265
J Cataract Refract Surg. 2010 Feb;36(2):299-307
pubmed: 20152614
Exp Eye Res. 2018 Mar;168:100-106
pubmed: 29357284
Optom Vis Sci. 2011 Aug;88(8):1014-9
pubmed: 21552175
Am J Ophthalmol. 2016 Nov;171:88-94
pubmed: 27590121
Br J Ophthalmol. 2008 May;92(5):630-4
pubmed: 18441173
Invest Ophthalmol Vis Sci. 2012 Jun 26;53(7):4076-84
pubmed: 22491402
Case Rep Ophthalmol Med. 2013;2013:906920
pubmed: 23476848
Arch Toxicol. 2019 May;93(5):1401-1415
pubmed: 30778631
Retina. 2016 Jul;36(7):1381-7
pubmed: 26655614
J Photochem Photobiol B. 2001 Nov 15;64(2-3):144-61
pubmed: 11744401
Retina. 2014 Dec;34(12):2388-96
pubmed: 25380069
Surv Ophthalmol. 2008 Jul-Aug;53(4):359-67
pubmed: 18572053
Prog Retin Eye Res. 2016 Jan;50:34-66
pubmed: 26541886
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1981-9
pubmed: 10845625
Jpn J Ophthalmol. 2011 Jul;55(4):428-430
pubmed: 21633809
Retin Cases Brief Rep. 2011 Summer;5(3):223-6
pubmed: 25390169
Retina. 2012 Feb;32 Suppl 1:28-43
pubmed: 22451949
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):3011-3019
pubmed: 30025122
Retin Cases Brief Rep. 2013 Fall;7(4):371-5
pubmed: 25383813
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3616-3627
pubmed: 28728169
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2552-63
pubmed: 27163768
J Physiol. 1988 Jan;395:577-87
pubmed: 3411488
Acta Ophthalmol Scand. 2006 Feb;84(1):4-15
pubmed: 16445433
Arch Ophthalmol. 2012 Dec;130(12):1540
pubmed: 23229694
Ophthalmology. 2016 Mar;123(3):570
pubmed: 26902564
Eye (Lond). 2019 Mar;33(3):492-504
pubmed: 30546136
Mol Aspects Med. 2005 Dec;26(6):459-516
pubmed: 16309738
Int J Toxicol. 2002 Nov-Dec;21(6):473-90
pubmed: 12537644
J Occup Med. 1983 Mar;25(3):203-10
pubmed: 6842311
Arch Biochem Biophys. 2001 Jan 1;385(1):28-40
pubmed: 11361022
FEBS Lett. 1997 Nov 24;418(1-2):91-7
pubmed: 9414102
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4777-85
pubmed: 19628740
Photodiagnosis Photodyn Ther. 2017 Jun;18:264-266
pubmed: 28347866
Arch Ophthalmol. 2004 May;122(5):750-7
pubmed: 15136324
BMC Ophthalmol. 2018 Dec 20;18(1):331
pubmed: 30572865
Vision Res. 1987;27(9):1581-7
pubmed: 3445490
Photochem Photobiol. 1979 Apr;29(4):735-43
pubmed: 109869

Auteurs

Akira Obana (A)

Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
Photochemical Medicine Department, Photon Medical Research Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Yuko Gohto (Y)

Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.

Ryo Asaoka (R)

Department of Ophthalmology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH